MedPath

Assessing levels of Periostin and DKK-1, for periodontal disease and diabetes before and after treatment.

Not Applicable
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2023/04/051408
Lead Sponsor
Suganya T
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

subjects with diagnosis of stage III grade B periodontitis.

well controlled diabetes subjects will be selected.

subjects should not have atleast 20 natural teeth excluding third molars.

subjects with normal lipid profile.

Exclusion Criteria

pregnant and lactating females. smokers and alcoholics

subjects with other systemic conditions rheumatoid arthritis, cardiovascular abnormalities, use of immunosuppressive medications, and other infectious chronic diseases.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare and correlate the clinical parameters and levels of Periostin and DKK1 in <br/ ><br>GCF and Serum in periodontally healthy, stage III Grade B periodontitis subjects with and without Type 2 Diabetes mellitus before and 3 months after NSPTTimepoint: 12 weeks
Secondary Outcome Measures
NameTimeMethod
1. To estimate the levels of Periostin and DKK-1 in the gingival crevicular (GCF) and serum in systemically and periodontally healthy subjects, Stage III Grade B periodontitis patients with and without Type 2 diabetes mellitus. <br/ ><br>2.To estimate the levels of Periostin and DKK-1 in the GCF and serum in Stage III Grade B periodontitis patients with and without Type 2 diabetes mellitus patients 3 months after NSPT. <br/ ><br>3. To explore the possibility of using DKK-1 as a bone resorptive marker in periodontal disease progression.Timepoint: 12 weeks
© Copyright 2025. All Rights Reserved by MedPath